×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear
clinical
3,559 words
KG: ent-clin-2d2b9c14
2026-03-28
section:clinical-trials
kind:clinical-trial
topic:psp
topic:oga-inhibitor
topic:tauopathy
Contents
FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear Palsy
Knowledge Graph
Related Hypotheses (17)
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Phase-Separated Organelle Targeting
Score: 0.52
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.49
Stress Granule Phase Separation Modulators
Score: 0.49
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Lysosomal Enzyme Trafficking Correction
Score: 0.49
Lysosomal Membrane Repair Enhancement
Score: 0.45
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.44
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.42
Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.42
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
Pharmacological Enhancement of APOE4 Glycosylation
Score: 0.37
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
Show 12 more
Related Analyses (7)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Show 2 more
Related Experiments (25)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
Show 20 more